Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn)
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
H.R. 5539 - ORPHAN Cures Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
Issues related to access and coverage in Medicare program.
Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Duration: August 1, 2018
to
present
General Issues: Medicare/Medicaid , Health Issues
Spending: about $1,110,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
In Q4, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on Jan. 20.
Original Filing: 301533983.xml
Lobbying Issues
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn)
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
H.R. 5539 - ORPHAN Cures Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
Issues related to access and coverage in Medicare program.
Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301516527.xml
Lobbying Issues
Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn)
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Issues related to access and coverage in Medicare program.
Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, H.R.2880 - Protecting Patients Against PBM Abuses Act.
H.R. 5539 - ORPHAN Cures Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301489935.xml
Lobbying Issues
Access to DME-infused drugs in the home.
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Issues related to access and coverage in Medicare program.
Support for S.476 Maintaining Investments in New Innovation Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3281 - The Transparent PRICE Act, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301466704.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies(DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable MedicalEquipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas;Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions included in Title I - Subtitle B of PL.117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Issues related to access and coverage in Medicare program.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301438188.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions included in Title I - Subtitle B of PL.117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Issues related to access and coverage in Medicare program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Inclusion of study on genetically targeted technologies in S. 4348 - FDASLA Act of 2022 and H.R. 7667 - Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415113.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions included in Title I - Subtitle B of PL.117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Issues related to access and coverage in Medicare program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Inclusion of study on genetically targeted technologies in S. 4348 - FDASLA Act of 2022 and H.R. 7667 - Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301390107.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill.
Issues related to access and coverage in Medicare Part D program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Inclusion of study on genetically targeted technologies in S. 4348 - FDASLA Act of 2022 and H.R. 7667 - Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301365082.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Issues related to access and coverage in Medicare Part D program.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301335705.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301311278.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions related to vial wastage rebates in Medicare Part B including in Sec. 102 of S. 2164/H.R. 19 - Lower Costs, More Cures Act of 2021 and Sec. 90004 of H.R. 3684 - Infrastructure Investment and Jobs Act.
Provisions included in Subtitle J - Drug Pricing of H.R. 5376 - Build Back Better Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301284736.xml
Lobbying Issues
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN).
Provisions related to vial wastage rebates in Medicare Part B including in Sec. 102 of S. 2164/H.R. 19 - Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301264495.xml
Lobbying Issues
Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Implementation of Home Infusion Therapy Benefit.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234728.xml
Lobbying Issues
CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Public Law 115-123. Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Most Favored Nation (MFN) Model, (CMS-5528-IFC).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on Oct. 14, 2020.
Original Filing: 301209611.xml
Lobbying Issues
CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Public Law 115-123.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on July 15, 2020.
Original Filing: 301188095.xml
Lobbying Issues
CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC and CMS-5531-IFC.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on April 19, 2020.
Original Filing: 301172474.xml
Lobbying Issues
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $60,000. The report was filed on Jan. 17, 2020.
Original Filing: 301108948.xml
Lobbying Issues
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $40,000. The report was filed on Oct. 21, 2019.
Original Filing: 301073497.xml
Lobbying Issues
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 2543, the Prescription Drug Pricing Reduction Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $50,000. The report was filed on July 16, 2019.
Original Filing: 301046725.xml
Lobbying Issues
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. H.R. 2113, Prescription Drug STAR Act of 2019. S. 551, the REFUND Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $40,000. The report was filed on April 22, 2019.
Original Filing: 301033480.xml
Lobbying Issues
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892 - Bipartisan Budget Act of 2018.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $30,000. The report was filed on Jan. 22, 2019.
Original Filing: 301017280.xml
Lobbying Issues
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892 - Bipartisan Budget Act of 2018.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, THE MCMANUS GROUP lobbied for Alnylam Pharmaceuticals , earning $30,000. The report was filed on Oct. 22, 2018.
Original Filing: 300995411.xml
Lobbying Issues
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
The McManus Group filed a lobbying registration on Aug. 14, 2018 to represent Alnylam Pharmaceuticals, effective Aug. 1, 2018.
Original Filing: 300980708.xml
Issue(s) they said they’d lobby about: Reimbursement and access to novel therapeutics based on RNA interference and related administration costs. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...